Update on the optimal use of voriconazole for invasive fungal infections by Lat, Asma & Thompson, George R
© 2011 Lat and Thompson, publisher and licensee Dove Medical Press Ltd. This is an Open Access 
article which permits unrestricted noncommercial use, provided the original work is properly cited.
Infection and Drug Resistance 2011:4 43–53
Infection and Drug Resistance Dovepress
submit your manuscript | www.dovepress.com
Dovepress 
43
RevIew
open access to scientific and medical research
Open Access Full Text Article
DOI: 10.2147/IDR.S12714
Update on the optimal use of voriconazole  
for invasive fungal infections
Asma Lat1 
George R Thompson III2
1Department of Pharmacy,  
New York-Presbyterian Hospital,  
Columbia University Medical Center, 
New York, NY, USA; 2Department 
of Medical Microbiology and 
Immunology, Coccidioidomycosis 
Serology Laboratory, and the 
Department of Medicine, Division  
of Infectious Diseases, University  
of California-Davis, Sacramento,  
CA, USA
Correspondence: George R Thompson III 
University of California-Davis, 
Coccidioidomycosis Serology Laboratory, 
One Shields Avenue, Rm 3134, Davis, CA 
95616, USA 
Tel +1 530 752 1757 
Fax +1 530 752 8692 
email grthompson@ucdavis.edu
Abstract: Voriconazole is an extended-spectrum triazole with excellent bioavailability that 
has now become the treatment of choice for aspergillosis. It has a unique side effect profile 
compared with other azoles, as well as a number of clinically important drug–drug interactions. 
These factors, along with a correlation between increased serum levels and improved outcomes, 
have prompted an interest in therapeutic drug monitoring of this agent. The pharmacology and 
clinical outcomes data of voriconazole are presented in this review.
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Introduction
Invasive fungal infections (IFIs) are responsible for significant morbidity and mortality. 
Mortality from invasive candidiasis has decreased in recent years, but diseases due 
to other fungi, including Aspergillus spp., have led to an overall increase in deaths 
from IFIs.1–4 The number of immunocompromised patients at risk for IFIs has also 
increased during this same time period as more patients are exposed to immunosup-
pressants and intense chemotherapy regimens.5 Amphotericin B deoxycholate has 
traditionally been the foundation of treatment for IFIs since its approval by the US 
Food and Drug Administration (FDA) in the 1950s. However, several new broad-
spectrum antifungals, including voriconazole, have become available during the past 
15 years in an effort to improve treatment outcomes and minimize drug toxicities in 
the growing at-risk population. Voriconazole, a widely utilized mold-active triazole, 
is the subject of this review.
Pharmacology
Azole antifungals
Ketoconazole, an imidazole antifungal, was the first systemic azole approved by the FDA 
in 1979. Use of the imidazoles has since been restricted to topical   treatment of superficial 
fungal infections due to the lack of enzyme specificity and e  nsuing adverse effects with 
systemic therapy. Alteration of ketoconazole’s structure resulted in the development 
of the initial triazole, fluconazole. Fluconazole was c  onsidered an advancement over 
previous azole antifungals due to its enhanced safety and efficacy, but its spectrum of 
activity lacked coverage against clinically important molds, i  ncluding Aspergillus spp. 
Fluconazole was followed chronologically by the i  ntroduction of itraconazole, which 
added activity against Aspergillus. The clinical use of i  traconazole, however, is limited 
by its low oral bioavailability and side effect profile. The expanded-spectrum triazoles Infection and Drug Resistance 2011:4 submit your manuscript | www.dovepress.com
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voriconazole and posaconazole were then f  ormulated to 
provide potent a  ctivity against a variety of yeasts and molds 
while r  educing treatment-limiting adverse effects.6 These 
agents have s  ubsequently become the p  referred agents for 
the t  reatment and prophylaxis of i  nvasive a  spergillosis, 
respectively.7 This review will highlight the in vitro activ-
ity and m  echanisms of resistance,   pharmacokinetics/
p  harmacodynamics, rationale for therapeutic drug m  onitoring 
(TDM), clinical efficacy, adverse effects, and drug   interactions 
associated with voriconazole.
Mechanism of action
The azoles enact their antifungal effects within the fungal 
cell membrane by blocking the P450 (CYP)-dependent 
d  emethylation of lanosterol, leading to the inhibition of 
ergosterol synthesis (Figure 1). This process causes toxic 
methylsterols to accumulate in the fungal cell membrane 
and prevents fungal cell growth and replication. Differences 
between azoles in antifungal potency and activity are attrib-
uted to differences in their affinity for the 14-α-demethylase 
enzyme. The toxicity and drug interaction profiles of the 
azoles, including voriconazole, are due to cross-inhibition 
of various human CYP-dependent enzymes. Voriconazole, 
like other triazoles, is fungistatic against most yeasts but has 
fungicidal activity against molds, including Aspergillus.8–10
In addition to the antifungal activity described previ-
ously, the triazoles also possess immunomodulatory effects 
that have only recently been identified and are still being 
elucidated. These indirect antifungal effects are likely to gain 
more relevance in clinical practice as IFIs disproportionately 
affect patients with immunodeficiencies. In vitro models 
have shown that ergosterol depletion enhances fungal cell 
susceptibility to both oxidative and nonoxidative phagocytic 
damage.11 Voriconazole also specifically induces the expres-
sion of toll-like receptor 2, nuclear factor-κB, and tumor 
necrosis factor alpha in monocytes.12
In vitro activity and mechanisms  
of resistance
Voriconazole, like other extended-spectrum triazoles, is active 
against a wide variety of invasive mycoses, including Can-
dida, Cryptococcus, most dimorphic fungi, Aspergillus, and 
other yeasts and hyaline molds (Table 1). Voriconazole is not 
active against Sporothrix schenckii and members of the Zygo-
mycetes group, however. Cross-resistance against Candida 
spp. is common, and only about 30% of fluconazole-resistant 
C. albicans, C. glabrata, C. tropicalis, and C. rugosa isolates 
remain susceptible to voriconazole; thus, fluconazole is often 
used as a surrogate marker of voriconazole r  esistance.13,14 
Therefore, susceptibility t  esting is recommended prior 
to usage of voriconazole for candidiasis se  condary to 
fluconazole-resistant strains. The European Committee on 
Antimicrobial Susceptibility T  esting (EUCAST) defines 
minimum inhibitory c  oncentrations (MICs) #0.125 µg/
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Figure 1 Targets of systemic antifungal agents.
Reproduced with permission from reference 6.Infection and Drug Resistance 2011:4 submit your manuscript | www.dovepress.com
Dovepress 
Dovepress
45
voriconazole for invasive fungal infections
mL as susceptible for C. albicans, C. parapsilosis, and 
C. tropicalis, whereas the Clinical and Laboratory Standards 
Institute (CLSI) does not d  ifferentiate between Candida spp. 
and defines MICs # 1 µg/mL as being susceptible.15,16
Mutations within the ERG11 gene (CgERG11), 
which encodes the azole target enzyme, and   upregulation 
of the CgCDR1 and CgCDR2 genes, which encode 
drug efflux pumps, lead to voriconazole resistance in 
C.   glabrata.17 Similar mechanisms have also been   identified 
in other   voriconazole-resistant Candida spp. Unlike other 
  Candida spp., the majority of C. krusei isolates remain 
susceptible to voriconazole, despite inherent flucon-
azole   resistance, likely due to more avid binding to the 
14α-demethylase target enzyme.18,19
Resistance to mold-active triazoles among   Aspergillus spp. 
is still considered to be an uncommon occurrence, though 
specific rates are not completely known, as few centers 
actively monitor for resistance. Alteration of the 14α-sterol 
demethylase enzyme encoded by the CYP51A and CYP51B 
genes appears to be the most c  ommonly described 
  mechanism of resistance to this class. An amino acid 
  substitution at   position M220 confers panazole   resistance, 
and a substitution at position G54 leads only to itraconazole 
and posaconazole resistance.20,21 Several other novel amino 
acid   modifications have also recently been described.22,23 
  Conflicting reports exist regarding the exact incidence of 
resistance to   voriconazole in Aspergillus spp. A recent 
survey detected voriconazole MICs . 2 µg/mL in less 
than 1% of 771   clinical Aspergillus spp. isolates, whereas 
other researchers have noted   increasing resistance during 
the last 5 years.24–26 Notably, emerging mechanisms of 
resistance yet to be fully characterized may be responsible 
for the recent increase in   voriconazole-resistant Aspergillus 
in some g  eographic locales.26 Given the   evolving nature of 
resistance in the face of increasing use of   broad-spectrum 
azoles, it seems prudent to maintain vigilance in s  urveillance 
activities.
Pharmacokinetics and pharmacodynamics
Voriconazole, unlike other broad-spectrum triazoles, is 
available in both oral and intravenous dosage forms. The 
intravenous formulation is solubilized in sulfobutyl ether 
β-cyclodextrin (SBECD).27 Steady-state levels are attained 
after 5–6 days when 3–6 mg/kg/day of voriconazole is 
administered. However, intravenous loading doses reduce 
the time to reach steady state to only 1 day.28 Similarly, oral 
loading doses also lead to achievement of steady-state levels 
within 24 hours. Oral bioavailability is .90% when doses 
are administered 1 hour prior to or after a meal.29 Absorption 
is not reliant on gastric acidity, but fatty foods reduce 
  bioavailability by approximately 20%.30 Voriconazole has a 
large volume of distribution (4 L/kg) and is   approximately 
60% protein bound. Tissue levels may exceed serum levels, 
and cerebrospinal fluid (CSF) levels, which are lower than 
brain levels, are usually about 50% concomitant serum 
values.31 Less than 2% of active drug is excreted renally.
Voriconazole has linear pharmacokinetics in   children 
but exhibits nonlinear pharmacokinetics in adults, which can 
lead to complicated dosing scenarios. The n  onlinear k  inetics 
seen in adults are likely due to saturable   metabolism.28 
V  oriconazole is hepatically metabolized via the CYP450 
system through the CYP2C9, CYP2C19, and CYP3A4 
  isoenzymes. Not surprisingly, these isoenzymes are also 
responsible for the majority of drug–drug interactions 
  associated with voriconazole (see Drug–drug interactions).
Like other triazoles, area under the curve (AUC)/MIC 
is the pharmacodynamic parameter that best describes 
  voriconazole’s antifungal efficacy. Nonlinear pharmacoki-
netics and high interpatient variability, however, compli-
cate the evaluation of concentration-effect relationships in 
humans (see Therapeutic drug monitoring).27
Dosing
As mentioned previously, loading doses are recommended 
for both the oral and intravenous formulations. In patients 
aged $12 years, intravenous dosing consists of 6 mg/kg 
twice daily on day 1 followed by 4 mg/kg twice daily for 
the remainder of treatment. Oral dosing in adults is weight 
based. Per the package insert, adult patients weighing .40 kg 
should receive 400 mg twice daily on day 1 followed by 
200 mg twice daily until the end of therapy, whereas a 200 mg 
Table 1 voriconazole spectrum of activity
Organism Activity
Aspergillus species +
Candida speciesa +
Cryptococcus neoformans +
Coccidioides species +
Blastomyces +
Histoplasma species +
Fusarium species +
Scedospermium apiospermum +
Scedosporium prolificans ±
Sporothrix schenckii -
Zygomycetes -
Notes: Plus (+) signs indicate activity against the listed organism. Minus (-) signs indicate 
a lack of activity against the listed organism. Plus–minus signs (±) indicate variable 
activity against the listed organism. aCross-resistance with fluconazole common.
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twice-daily loading dose on day 1 followed by 100 mg 
twice daily, is recommended for those weighing ,40 kg.27 
However, many clinicians opt to approximate oral dosing to 
intravenous dosing by administering the loading (6 mg/kg) 
and maintenance (4 mg/kg) doses rounded up to the nearest 
pill size (oral formulation available as 200 mg and 50 mg 
tablets).7 Pediatric dosing reflects the rapid metabolism and 
linear kinetics seen in this population and is recommended at 
7 mg/kg twice daily intravenously and 200 mg orally twice 
daily, both without loading doses.
Dose adjustments are required for patients with mild to 
moderate hepatic dysfunction (Child-Pugh Class A and B). 
The standard loading dose should be provided to these patients, 
but maintenance doses should be reduced by 50%.32 Studies 
have not adequately evaluated the safety of v  oriconazole in 
severe liver disease (Child-Pugh Class C). Dosage a  djustment 
is not required in patients with renal   insufficiency if oral 
v  oriconazole is administered, but the SBECD vehicle   present 
in the intravenous formulation may accumulate in these 
patients. For this reason, intravenous voriconazole should 
be avoided when creatinine clearance is ,50 mL/min unless 
the potential benefit outweighs the risk.27
Like other triazoles, voriconazole is teratogenic in ani-
mals and should be avoided during pregnancy and while the 
mother is breastfeeding.33
Therapeutic drug monitoring
Voriconazole has a number of complex pharmacokinetic 
properties that make TDM an integral component of opti-
mizing antifungal therapy with this agent. A large degree of 
pharmacokinetic variability at standard doses, both inter- and 
intrapatient, is an important characteristic that necessitates 
TDM of voriconazole.34 Additionally, a large number of 
drug–drug interactions complicate treatment with voricon-
azole by influencing its pharmacokinetics or the pharmacoki-
netics of other drugs that are given simultaneously.35
The pharmacokinetic variability seen with voriconazole 
is likely multifactorial. First, the activity of the primary 
m  etabolic enzyme CYP2C19 P450 differs significantly 
between ethnic groups.36 Genetic polymorphisms of the 
CYP2C19 enzyme result in patients who are homozygous 
extensive metabolizers, heterozygous extensive m  etabolizers, 
or homozygous poor metabolizers. Patients of Asian e  thnicity 
are likely to be homozygous poor metabolizers, which 
p  redisposes them to higher voriconazole serum levels. This 
is in stark contrast with Caucasians, about 75% of whom are 
homozygous extensive metabolizers and thus have lower 
voriconazole concentrations. A commercial CYP2C19 
g  enotype testing product has recently become available 
(Genelex, Seattle, WA, USA), but it is unclear whether use 
of this assay will gain widespread use and how clinicians will 
use results from the test to adjust empiric dosing regimens.
Voriconazole is known to interact with numerous medi-
cations that are likely to be used in patients at high risk for 
IFIs, including tacrolimus, cyclosporine, and sirolimus. 
These drugs all undergo significant changes in their 
pharmacokinetics when coadministered with voriconazole.6 
Additionally, several drugs that are often used in patients with 
HIV , such as rifamycins, phenytoin, long-acting barbiturates, 
and carbamazepine, markedly decrease voriconazole levels 
and may lead to clinical failure when given concurrently with 
voriconazole.6 It has recently been reported that autoinduc-
tion of voriconazole metabolism at higher doses is possible 
and that voriconazole trough levels seem to decrease over 
time without any apparent explanation.37,38 All of these 
identified issues may considerably alter voriconazole phar-
macokinetics and thus make TDM an attractive means of 
monitoring treatment.
In addition to the aforementioned pharmacokinetic 
issues that support the use of TDM, clinical outcomes data 
exist that cohesively associate low voriconazole serum 
levels with poor outcomes and thus further strengthen the 
a  rgument for TDM. Denning et al were the first group to 
report this correlation.39 They found high failure rates (60%) 
in patients with invasive aspergillosis and random voricon-
azole levels #0.25 µg/mL. Smith et al subsequently studied 
17 patients clinically failing voriconazole treatment (mostly 
for i  nvasive aspergillosis) and had serum concentrations 
taken.40 All 17 patients had levels ,2.51 µg/mL, which the 
authors noted is below the median value seen in clinical trials 
of voriconazole. I  nterestingly, weight did not seem to affect 
voriconazole serum concentrations, which is consistent with 
the FDA briefing document on voriconazole.35 Voriconazole 
levels ,2 µg/mL led to dose increases in 11 patients, and 
8 of these 11 patients survived their infections. Another 
important fi  nding from this study was that all patients with a 
voriconazole level .2.05 µg/mL survived, whereas only 8 of 
18 patients with a level ,2.05 µg/mL lived (P , 0.025). This 
study provided important information regarding the relation-
ship between voriconazole serum concentrations and clinical 
outcomes but is limited by the low number of patients and 
a lack of a clear definition of when levels were taken.
Pascual et al conducted the most important study to date 
examining the relationship between voriconazole serum levels 
and clinical outcomes.41 The authors obtained 181 voriconazole 
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trough levels between 1 µg/mL and 5.5 µg/mL. They chose 
this range because the MIC90 for most organisms targeted 
by voriconazole is between 0.5 µg/mL and 1 µg/mL, and 
toxicities generally occur at serum levels .5.5 µg/mL. An 
important distinction between this study and the previously 
mentioned studies is that the authors provide recommenda-
tions for voriconazole dose changes based on trough levels 
obtained. This study also provided several important results 
that should be taken into consideration when managing 
specific patients in clinical practice. First, the authors found 
substantial intradose variability between serum levels from 
individual patients. Second, though the authors state that 
there was no significant difference in trough levels between 
the different daily dosages ranging from #5 mg/kg/day 
to $8 mg/kg/day, the mean trough concentration appeared to 
be substantially higher in the $8 mg/kg/day group than in the 
others (2.9 vs 1.7 vs 1.2 vs 1.7). Trifilio et al also failed to 
find a significant correlation between dose and voriconazole 
trough levels.42
Pascual et al found that patients with voriconazole 
serum levels ,1.0 µg/mL had significantly lower response 
rates than those patients with levels .1.0 µg/mL (46% vs 
12%; P = 0.02), and patients with levels ,1.0 µg/mL were 
more likely to be receiving oral therapy.41 The median daily 
oral voriconazole dose was 6 mg/kg, and patients receiving 
intravenous treatment had a median dose of 7.5 mg/kg/day. 
This raises an important point regarding dosing of vori-
conazole, as the package insert for voriconazole indicates 
weight-based dosing for the intravenous formulation but 
recommends a fixed dose for the oral formulation. Thus, 
when patients are transitioned from intravenous to oral 
voriconazole, it is possible for substantial dose reductions 
to occur, p  otentially p  lacing them at risk for therapeutic 
failure. Of note, all six patients whose infections progressed 
while receiving voriconazole regimens that led to levels 
of ,1.0 µg/mL exhibited clinical improvement once their 
doses were increased to achieve serum troughs .1.0 µg/mL. 
Additional statistical analysis predicted a 70% success rate 
with voriconazole troughs .1.0 µg/mL.
Although low serum voriconazole levels predict poor 
clinical outcomes, adverse effects due to voriconazole have 
been associated with increased voriconazole concentrations. 
The FDA briefing document for voriconazole indicates that 
a significant correlation exists between increased voricon-
azole maximum concentration (Cmax) and AUC and elevated 
transaminases and thus recommends that serum voriconazole 
levels should not surpass 5.0 µg/mL.35 Abnormalities in liver 
function tests are a well-known adverse effect of azoles and 
were the primary toxicity associated with voriconazole until 
recently. Central nervous system (CNS) adverse effects, 
including hallucinations, are increasingly being reported 
in the literature. The study by Pascual et al noted that five 
(31%) patients with voriconazole serum levels .5.5 µg/mL 
e  xperienced hallucinations, but no patients with serum 
concentrations ,5.5 µg/mL reported similar toxicities.41 
A separate study by Zonios et al also described similar 
o  ccurrences in 12 of 72 patients.43 Eight of the 12 patients 
reported hallucinations with the initial loading doses of 
intravenous voriconazole, and five of six patients with serum 
voriconazole trough concentrations had levels .5.2 µg/mL. 
These data provide further evidence that elevated serum 
voriconazole trough concentrations are correlated not only 
with hepatoxicity but also with CNS adverse effects.
Despite evidence that TDM may be a necessary compo-
nent of managing voriconazole therapy due to unpredictable 
pharmacokinetics and the correlation with clinical outcomes 
and toxicities, many clinicians do not routinely employ TDM. 
This underutilization of TDM may be due to the delay in 
obtaining results in a timely manner, as few laboratories 
perform the assay. As more data accumulate in this research 
area, it is possible that voriconazole TDM will become the 
standard of care as a means to optimize therapy with this 
important antifungal.
Safety and tolerability
Voriconazole is typically well tolerated, and the side effect pro-
file is similar to that of other triazoles but with a few notable 
differences (Table 2). In a study that compared voriconazole 
with fluconazole for esophageal candidiasis, patients receiving 
voriconazole experienced more treatment-related side 
Table 2 Adverse effects of voriconazole
Organ system Adverse effect
Special senses Altered light perception 
Photophobia, blurred vision (,30%)
Cardiovascular system  QTc prolongation
Gastrointestinal disorders Nausea, vomiting (,5%) 
Abdominal pain (,10%)
endocrine system Adrenal insufficiency (rare)
Liver and biliary system Increased transaminases (,15%) 
Hepatitis (rare)
Central nervous system Hallucinations, confusion (10%) 
Headache
Skin and appendages Pruritis, rash (,10%) 
Photosensitivity (,2%)
Immunologic Anaphylaxis reported
Maximum tolerated dose in 
clinical trials
800 mg/day (10 mg/kg/day)
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effects than those who received fl  uconazole (30% vs 14%). 
Gastrointestinal side effects were frequently e  ncountered 
and were similar between the two drugs (9%), but the most 
common toxicity due to voriconazole was transient, infusion-
related abnormal vision that was not sight threatening (23%). 
Visual effects may manifest as altered color discrimination, 
blurred vision, appearance of wavy lines and bright spots, 
and photophobia. This   distinctive adverse effect usually 
occurs 30 minutes after infusion, subsides 30 minutes later, 
is not known to cause long-term retinal sequelae, and tends to 
dissipate after the first week of treatment.27 Infusion-related 
side effects were also the most common voriconazole-related 
adverse reactions in a large, randomized, multicenter trial that 
compared intravenous voriconazole with liposomal amphot-
ericin B for empiric antifungal therapy in febrile neutropenia.44 
Nearly 25% of patients reported photopsia in this study, but 
discontinuation of voriconazole due to treatment-related side 
effects was uncommon.
More familiar side effects of voriconazole treatment 
include skin rash and transaminase elevation.39 Most rashes 
are mild, but severe reactions, including Stevens–Johnson 
syndrome and toxic epidermal necrolysis, have been observed 
in a few patients. Patients should be warned to avoid direct 
sunlight, because photosensitivity reactions are possible. 
Recently, several reports have described a possible associa-
tion between long-term voriconazole use and skin cancer, 
including aggressive squamous cell carcinoma and mela-
noma, in the setting of severe photosensitivity reactions.45–49 
Surveillance for skin cancer formation in patients requiring 
long-term voriconazole therapy, particularly those who 
exhibit photosensitivity or chronic photodamage, is now 
recommended. Monitoring of LFTs is recommended at 
baseline, within the first 2 weeks of treatment initiation, and 
periodically thereafter; fulminant hepatic failure has been 
rarely reported.50 Similar to other triazoles, QTc prolonga-
tion has been attributed to voriconazole, and concurrent 
QTc-prolonging agents should be avoided if possible.51 
As described previously (see Therapeutic drug monitoring), 
serum trough concentrations .5.5 µg/mL have been corre-
lated with CNS toxicities unique to voriconazole compared 
with other triazoles.41,43
Animal studies indicate that accumulation of SBECD 
(the solubilizing agent used in the intravenous voriconazole 
formulation) can result in hepatic and renal toxicities as a 
result of massive cytoplasmic vacuolation.27 The minimal 
lethal dose in animal experiments was 2000 mg/kg, however, 
and acute toxicities were uncommon. Available clinical data 
in humans with impaired renal function and those undergoing 
renal replacement therapies also indicate an accumulation of 
SBECD during treatment with intravenous voriconazole, but 
toxic effects have not been observed.52–54 Larger, prospective 
studies are needed to fully evaluate the effects of intravenous 
voriconazole in patients with renal dysfunction.
Drug–drug interactions
Treatment with voriconazole is often complicated by the 
  potential for myriad drug–drug interactions due to its 
metabolism by and inhibition of CYP450 2C19, 3A4, 
and 2C9 enzymes (Tables 3 and 4).55–64 Inhibition of 
CYP3A4 can lead to a significant increase in serum levels 
of cyclosporine, tacrolimus, warfarin, methadone, statins, 
benzodiazepines,   diltiazem, vinca alkaloids,   sulfonylureas, 
omeprazole,   phenytoin, protease inhibitors, and nonnucleo-
side reverse transcriptase inhibitors. Dose   adjustments are 
required for most of these agents, as well as monitoring of 
serum levels and/or markers of their activity and   toxicity. 
When voriconazole is discontinued, care must be taken 
to increase doses of these drugs as well. Potent CYP3A4 
inducers, such as rifampin, ca  rbamazepine, and long-acting 
barbiturates, can lead to decreased voriconazole serum 
concentrations and should be avoided in combination with 
  voriconazole. A  dditionally, complex two-way drug interac-
tions are also possible with voriconazole when used con-
comitantly with efavirenz,   phenytoin, and rifabutin.58,60 These   
drugs all lead to an appreciable reduction in   voriconazole 
levels, whereas voriconazole considerably increases their 
concentrations. Numerous drugs are contraindicated for use with 
voriconazole, i  ncluding   sirolimus, quinidine, ergot alkaloids, 
astemizole, and cisapride, due to the risk of life-threatening 
adverse reactions. Despite the contraindication with sirolimus 
listed in the package insert, many clinicians successfully 
administer the two drugs simultaneously by reducing the siroli-
mus dose by 90% and monitoring   sirolimus c  oncentrations.65–67 
Thus, voriconazole interacts with a   formidable list of drugs, 
Table 3 voriconazole interactions with CYP450 enzymes
Drug mechanism Activity
Inhibitor
2C19 +++
2C9 ++
3A4 ++
Substrate
2C19 +++
2C9 +
3A4 +
Note: Interactions from minimal (+) to extensive (+++).
Modified from reference 6.Infection and Drug Resistance 2011:4 submit your manuscript | www.dovepress.com
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and a careful evaluation of drug regimens is warranted prior 
to, during, and after voriconazole therapy to prevent serious 
toxicities and/or therapeutic failure.
Clinical evidence
The broad spectrum of antifungal activity of voriconazole 
has enabled its evaluation in a variety of clinical settings. The 
following sections describe the outcomes data for a number 
of invasive mycoses.
Invasive aspergillosis
Voriconazole has become the drug of choice for invasive asper-
gillosis based on the results of a large, open-label, r  andomized, 
multicenter clinical trial that compared primary treatment 
with voriconazole with amphotericin B d  eoxycholate and 
other licensed antifungal agents.7,68 A blinded expert review 
panel determined that outcomes and case definitions were well 
defined and thus included patients with definite or probable 
invasive aspergillosis. Patients were randomized to receive 
either intravenous v  oriconazole (two doses of 6 mg per kg of 
body weight on day 1, then 4 mg per kg twice daily for at least 
7 days) followed by 200 mg orally twice daily or intravenous 
amphotericin B deoxycholate (1–1.5 mg per kg per day). 
Treating physicians were allowed to switch antifungal therapy 
if patients were unable to tolerate the study drug to which 
they were randomized; this occurred more frequently in the 
amphotericin B treatment arm.
A total of 277 patients were enrolled: 144 to the 
  voriconazole arm and 133 to the amphotericin B arm. Not 
surprisingly, the vast majority of patients in this study (∼80%) 
had invasive pulmonary aspergillosis and had underlying 
hematologic malignancies or were recipients of stem cell 
transplants. At week 12, significantly more patients who 
received voriconazole exhibited a complete or partial response 
compared with those patients in the amphotericin B group 
(53% vs 32%; 95% confidence i  nterval [CI] 10.4–32.9). 
Increased survival was also seen in the voriconazole group at 
week 12 (72% vs 58%; P = 0.02). Side effects were seen less 
frequently with voriconazole compared with amphotericin B 
(13% vs 24%; P = 0.008). This landmark study proved the 
superiority of voriconazole over amphotericin B and thus 
profoundly altered the management of patients with invasive 
aspergillosis. Though voriconazole is considered an impor-
tant advancement in the treatment of aspergillosis, outcomes 
are still less than optimal. Addition of an echinocandin agent 
to voriconazole is an attractive option to possibly improve 
treatment outcomes.69,70 Prospective studies of combination 
therapy with an echinocandin compared with voriconazole 
monotherapy are ongoing to determine whether clinical 
outcomes in this devastating disease can be improved.
Candidemia
Voriconazole has been compared with amphotericin B 
deoxycholate followed by fluconazole for candidemia in 
nonneutropenic patients in a large, multicenter, open-label 
study.71 Patients were randomly assigned, in a 2:1 ratio, to 
either voriconazole (n = 283) or amphotericin B followed 
by fluconazole (n = 139), and the results were reviewed 
by an independent, blinded, data review committee. 
Voriconazole was noninferior to amphotericin B followed 
by fluconazole at 12 weeks after the end of treatment, with 
successful outcomes in 41% of patients in both treatment 
groups (95% CI for d  ifference -10.6%–10.6%). Time to 
Table 4 Summary of voriconazole-mediated drug–drug interactions
Type of interaction, drug Recommendation
Decreases voriconazole levels
Carbamazepine Contraindicated
Long-acting barbiturates Contraindicated
Rifampin Contraindicated
Ritonavir Avoid unless benefit  
outweighs risk
Levels increased by voriconazole
Astemizole Contraindicated
Cisapride Contraindicated
Cyclosporine Reduce cyclosporine dosage by  
half and monitor cyclosporine  
levels
ergot alkaloids Contraindicated
Omeprazole Reduce dosage by half
Quinidine Contraindicated
Sirolimus Contraindicated 
Reduce sirolimus dose by 90% 
and monitor sirolimus levels
Tacrolimus Reduce tacrolimus dosage by  
two-thirds and monitor 
tacrolimus levels
Terfenadine Contraindicated
warfarin Monitor prothrombin time and 
international normalized ratio
Decreases voriconazole levels 
and increases other drug levels
Rifabutin Contraindicated
Phenytoin Double voriconazole dosage and 
monitor for increased phenytoin 
levels
efavirenz Double voriconazole dosage and 
reduce efavirenz dose by half
Levels likely increased by 
voriconazole: sulfonylureas, 
statins, vinca alkaloids, calcium 
channel blockers, benzodiazepines 
Monitor effect of drug and 
consider decreasing dosage 
when voriconazole is started
Modified from reference 27.Infection and Drug Resistance 2011:4 submit your manuscript | www.dovepress.com
Dovepress 
Dovepress
50
Lat and Thompson
blood culture clearance with voriconazole was also similar 
to that with amphotericin B/fluconazole (median time to 
negative blood culture, 2.0 days), challenging the notion 
that a f  ungicidal agent is required for primary treatment 
of all cases of candidemia. Treatment discontinuations 
due to all-cause adverse events were more frequent in the 
voriconazole group, although most discontinuations were 
due to nondrug-related events, and there were significantly 
fewer serious adverse events and cases of renal toxicity than 
in the amphotericin B/fl  uconazole group.
The most recent Infectious Diseases Society of America 
(IDSA) clinical practice guidelines for invasive c  andidiasis 
assign a level AI recommendation to voriconazole for 
the treatment of candidemia in nonneutropenic patients.72 
The authors note that voriconazole provides little benefit over 
fluconazole for most cases of invasive candidiasis but may 
be recommended for C. krusei infections or as oral stepdown 
therapy of susceptible C. glabrata.
esophageal candidiasis
One of the earliest trials to evaluate the efficacy and safety 
of voriconazole was a multicenter, randomized, double-
blind, double-dummy trial versus fluconazole for esophageal 
candidiasis.73 This study compared voriconazole 200 mg 
orally twice daily with fluconazole 200 mg orally once daily 
for a minimum of 7 days after clinical resolution. There 
was no difference in outcomes between the two groups as 
determined by esophagoscopy, with success rates of 98% 
with voriconazole and 95% with fluconazole. Adverse events 
were similar between the two agents, but visual disturbances 
occurred more frequently in the voriconazole group. These 
side effects tended to resolve during continued therapy, and 
no long-term adverse visual outcomes were found. Though 
voriconazole is as effective as fluconazole for esophageal 
candidiasis, it is often considered a second- to third-line 
agent after both fluconazole and itraconazole.72
empiric treatment during febrile 
neutropenia
Empiric antifungal treatment with voriconazole during 
p  ersistent neutropenic fever was evaluated in a large, open-
label, multicenter study.44 Voriconazole was compared with 
liposomal amphotericin B in a controversial trial where it did 
not meet the prespecified composite endpoint for n  oninferiority. 
Outcomes for four of the five endpoints (survival 7 days after 
end of therapy, discontinuation of therapy, resolution of 
fever, successful treatment of any baseline f  ungal infection) 
favored liposomal amphotericin B but did not reach st  atistical 
si  gnificance. However, significantly fewer breakthrough 
IFIs, including aspergillosis, occurred in the voriconazole 
arm (2% vs 5%; P = 0.02). The FDA denied approval to 
voriconazole for empirical treatment of febrile n  eutropenia 
based on the failure to meet the predefined composite e  ndpoint, 
but the current IDSA candidiasis guidelines provide a BI 
r  ecommendation to voriconazole for the treatment of suspected 
invasive candidiasis in neutropenic patients.72
Antifungal prophylaxis
A recent randomized, double-blind trial sponsored by the 
Blood and Marrow Transplant Clinical Trials Network (BMT 
CTN) compared extended prophylaxis with voriconazole at 
200 mg twice daily with fluconazole 400 mg per day after 
myeloablative allogeneic hematopoietic stem cell transplant 
(HSCT).74 Fungal-free survival rates at day 180 were similar 
between the two azoles (75% with voriconazole vs 78% with 
fluconazole; P = 0.49). There was a trend toward fewer IFIs 
(7% vs 11%; P = 0.11) and aspergillosis (9 vs 17; P = 0.09) 
with voriconazole, as well as less frequent empiric antifungal 
therapy (24% vs 30%; P = 0.11). It should be mentioned that 
several centers have identified the use of voriconazole in 
neutropenic patients as a risk factor for subsequent pulmonary 
zygomycosis, and animal models suggest that voriconazole 
pre-exposure may increase the virulence of zygomycetes 
in the event of infection.75–77 Thus, although voriconazole 
is equivalent to fluconazole as antifungal prophylaxis for 
standard-risk HSCT recipients, there is insufficient evidence 
to promote it to a first-line prophylactic agent in this specific 
patient population.
Cryptococcosis
Voriconazole has potent in vitro activity against Crypto-
coccus neoformans and has good CSF penetration (see 
Pharmacokinetics and pharmacodynamics). No prospective 
clinical trials have been conducted with voriconazole for this 
infection, and only a few cases of salvage therapy have been 
reported.78 A response rate of 39% was noted in 18 patients 
who failed, were intolerant to, or had toxicity from conven-
tional therapy for cryptococcosis. At this time, there is little 
evidence to lead to a recommendation for voriconazole as a 
first-line agent in the treatment of invasive cryptococcosis.
endemic mycoses
Voriconazole has demonstrated in vitro activity against 
the endemic fungi (Histoplasma capsulatum, Blastomyces 
d  ermatitidis, Coccidioides immitis and posadasii, Penicillium 
marneffi, and Paracoccidioides brasiliensis), but infections Infection and Drug Resistance 2011:4 submit your manuscript | www.dovepress.com
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due to these organisms are usually treated with amphotericin 
B formulations, itraconazole or fluconazole.79–89 A few 
cases have reported efficacy with voriconazole in treating 
these organisms, but voriconazole cannot be routinely 
recommended for treatment of any endemic mycosis due 
to a lack of prospective trials and limited salvage data. It is 
notable that voriconazole does not exhibit reliable in vitro 
activity against Sporothrix schenckii and thus should not be 
considered as a treatment option for infections due to this 
particular endemic organism.81
Hyalohyphomyces
Voriconazole is an FDA-approved treatment for IFIs due 
to hyaline molds, including Fusarium, Scedosporium, and 
Pseudollescheria spp., based on case reports/series, as well 
as a lack of efficacious alternative treatment options.78,90 
These fungi have become significant pathogens in severely 
immunosuppressed patients, particularly allogeneic stem 
cell transplant recipients. In vitro activity against these 
species is less potent than for other fungal pathogens, 
and susceptibility testing is warranted when considering 
treatment with voriconazole for infections due to these 
organisms.
Conclusion
Voriconazole is an extended-spectrum triazole that has now 
become the treatment of choice for invasive aspergillosis, 
fusariosis, and scedosporiosis, but it cannot be recommended 
over fluconazole or other antifungals for most candidal 
infections. Voriconazole has a unique adverse effect profile 
compared with other azoles, but treatment is generally 
well tolerated. TDM of serum levels may become more 
widely utilized in order to optimize treatment outcomes and 
minimize toxicities with voriconazole.
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